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Valorisation 
 
The results of this thesis can be valorised by the relevant implications they have on the 
following aspects of Public Health at a national or European level. 
 
a. Saving financial resources by avoiding oversupply with pharmaceuticals 
 
In general, it should be stated that both prescription drugs and OTC drugs should be 
used according to need and after a careful risk–benefit evaluation only. In light of the 
high prevalence rates of drug use among a supposedly quite healthy sample of chil-
dren/adolescents in Germany, it may at first be critically questioned whether all drugs 
used by children/adolescents are really necessary from a medical perspective, not least 
in view of the fact that active pharmaceutical ingredients also have the potential to 
harm. Consumption of drugs is, of course, a consumption of private or public financial 
resources as well. The mean price of pharmaceuticals used by adolescents in Germany 
is around €9.75 for OTC drugs and €69.28 for prescription drugs. The results of this 
thesis suggest that, on average, an adolescent may use about 0.58 packages of OTC 
drugs and 0.24 packages of prescription drugs within an observation period of 4 weeks, 
creating monthly expenditures on drugs (OTC and prescription drugs together) of 
roughly €24 on average per adolescent. Furthermore, the findings of chapter 6 imply 
that the use of prescription drugs and OTC drugs also partly follows habitual patterns. 
Drug utilization during childhood may to a certain degree determine drug use during 
adolescence or adulthood and, hence, result in (probably avoidable) expenditures on 
pharmaceuticals in the future. Thus, detecting the ‘necessity’ of drug use already at an 
early stage in life and subsequent efforts to reduce drug utilization to the required 
amount could be a relevant contribution to keep the expenditures of statutory health 
insurance companies on pharmaceuticals under control. However, ‘necessity’ might be 
perceived differently by different individuals and needs to be defined accurately. 
 
b. Value of self-medication and over-the-counter drugs to society 
 
According to evidence based on studies conducted in the United States, Australia, and 
Brazil [1–3], self-medication with OTC drugs helps to relieve social security systems. 
Depending on the source, every dollar/Brazilian real spent on self-medication saves 4–7 
dollars/Brazilian reals for the health care systems. Savings can be derived from reduced 
costs for prescription drugs, avoided costs for physician visits, and maintenance of the 
population’s working productivity. A prerequisite for exploiting the potential benefits of 
OTC drugs is that they are used in time as ‘early intervention’ to prevent, e.g. sick leave 
or consultation with a physician, which additionally would be likely to result in using 
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cost-intensive prescription drugs (in Germany, prescription drugs are about six times 
more expensive than OTC drugs). However, as shown in chapter 5, lower social back-
ground may predict lower use of OTC drugs among adolescents. Furthermore, accor-
ding to the results from chapter 7, adolescents from a higher social background may be 
more likely to use higher priced OTC drugs. Thus, higher prices could generally discou-
rage particularly people from a lower socioeconomic background from taking medically 
advisable but not reimbursable OTC drugs. Against this background, reimbursement of 
at least some defined categories of OTC drugs by social security could also make sense 
economically in relation to public health expenses to avoid higher costs caused by de-
layed treatment. Of course, all OTC drugs (as well as prescription drugs) should be used 
properly. This highlights the importance of further fostering of personal health literacy 
and good medical and pharmaceutical advice that is ideally not influenced by conflicting 
economic interests. 
 Additionally, it could be worth reflecting on whether and how the role of pharma-
cists could be strengthened with regard to the reimbursability of OTC drugs when 
bought without a medical prescription. For instance, in Germany, in the meantime, an 
increasing number of statutory health insurance companies reimburse expenditures on 
OTC drugs again, but coverage normally still requires a physician’s prescription (causing 
consultancy fees) on an OTC prescription form, which can be presented for reimburse-
ment after having purchased the OTC drug at the pharmacy. 
 
c. Pharmaceuticals as an economic factor 
 
The pharmaceutical industry is one of Europe’s key markets. As mentioned in chapter 1, 
it generates a yearly turnover of about 190 billion euros in Europe and provides jobs for 
roughly 690,000 employees (figures for 2012 and 2013). Additionally, a substantial 
number of people are working in the public health care sector (e.g. some 150,000 peop-
le as pharmaceutical personnel alone in German community pharmacies [4]). Where 
pharmaceuticals promote health in any way, expenditures on pharmaceutical products 
appear to be justified. A proper use of, e.g. OTC drugs, may not only save costs for 
health insurance companies but also supports the health economy. However, according 
to the results in chapter 5, there might be an undersupply of OTC drugs especially in the 
socioeconomically lowest stratum of the (paediatric) population. Closing this supply gap 
could bring further revenues to the health economy and at the same time a health 
benefit to those who are presumably using fewer drugs than actually needed or at least 
recommended. However, market mechanisms have to make sure that OTC drugs as 
well as generic or innovative prescription drugs also remain affordable in the future, if 
necessary regulated by political measures. 
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d. Harmonization of supply with medicinal products across the European Union 
 
Health and access to healthcare services such as treatment with medicinal products are 
high values that should not be limited by national borders and, undoubtedly, a healthy 
population is also an important pillar of a productive and prosperous society. 
 The European Union promotes freedom of movement for goods, workers, services, 
and capital. Not least against the background of the new EU directive on patients’ rights 
in cross-border health care, it may not appear very meaningful if different rules apply 
for the same medicinal products across the various EU member countries, e.g. with 
regard to the classification of drugs into freely available, presciption only status, or 
narcotics, but also with regard to the coverage of medicinal products by social security. 
The case of emergency contraceptives (chapter 8) suggests that a centralized re-
commendation by the European Medicines Agency (EMA) can strongly contribute to 
harmonization of, e.g., the legal status of a medicinal product across the EU member 
countries. Therefore, centralized drug supply standards may help to reduce disparities 
between EU countries with regard to access to medicinal products (which, in a certain 
sense, also represents a social inequality) and might contribute to further promote 
European integration. 
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